Catalina Capital Group LLC Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Catalina Capital Group LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,325 shares of the company’s stock after purchasing an additional 43 shares during the period. Eli Lilly and Company accounts for about 1.1% of Catalina Capital Group LLC’s investment portfolio, making the stock its 18th biggest holding. Catalina Capital Group LLC’s holdings in Eli Lilly and Company were worth $3,339,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Chicago Capital LLC grew its holdings in shares of Eli Lilly and Company by 43.7% in the 4th quarter. Chicago Capital LLC now owns 38,522 shares of the company’s stock worth $29,739,000 after acquiring an additional 11,709 shares during the period. Means Investment CO. Inc. grew its holdings in shares of Eli Lilly and Company by 6.8% in the 4th quarter. Means Investment CO. Inc. now owns 3,221 shares of the company’s stock worth $2,487,000 after acquiring an additional 205 shares during the period. Abner Herrman & Brock LLC grew its holdings in shares of Eli Lilly and Company by 1.3% in the 4th quarter. Abner Herrman & Brock LLC now owns 26,857 shares of the company’s stock worth $20,734,000 after acquiring an additional 349 shares during the period. Family Investment Center Inc. grew its holdings in shares of Eli Lilly and Company by 6.1% in the 4th quarter. Family Investment Center Inc. now owns 400 shares of the company’s stock worth $309,000 after acquiring an additional 23 shares during the period. Finally, Magnolia Capital Advisors LLC grew its holdings in shares of Eli Lilly and Company by 27.0% in the 4th quarter. Magnolia Capital Advisors LLC now owns 583 shares of the company’s stock worth $450,000 after acquiring an additional 124 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 2.1 %

Shares of LLY opened at $827.41 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $785.48 billion, a P/E ratio of 89.45, a price-to-earnings-growth ratio of 1.72 and a beta of 0.42. The stock’s fifty day simple moving average is $784.69 and its 200 day simple moving average is $843.49. Eli Lilly and Company has a twelve month low of $682.53 and a twelve month high of $972.53.

Eli Lilly and Company declared that its board has approved a stock repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a $1.50 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.73%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on LLY. Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Wolfe Research started coverage on Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price on the stock. Barclays lowered their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. StockNews.com cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Truist Financial increased their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.